Latest News
Tiziana Life Sciences to Host Investor Call
04 November 2022
NEW YORK, November 04, 2022-- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the Company plans to host an investor call and...
Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman
03 November 2022
New York, November 3, 2022 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Panetta Partners Limited, an...
Tiziana Life Sciences Completes Enrollment of the First Patient Cohort for its Intermediate-Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients
02 November 2022
NEW YORK, November 02, 2022 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced completion of enrollment of the first patient cohort (n=4)...
Tiziana Life Sciences Starts Enrollment of the First Patient Cohort in its Intermediate-Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients
26 October 2022
NEW YORK, October 26, 2022 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced the start of enrollment of the first patient cohort...
Article: BioSpace published an article on Tiziana's plan to submit an IND for Intranasal Alzheimer's Treatment
19 October 2022
Tiziana Plans IND for Intranasal Alzheimer's Treatment with Promising CNS History
Tiziana Life Sciences Ltd Invites You to Join Us at The ThinkEquity Conference
19 October 2022
New York- October 19, 2022 - Tiziana Life Sciences Ltd (NASDAQ: TLSA), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, will be participating in The ThinkEquity Conference, which will take place on October 26, 2022...
Tiziana Life Sciences Plans to Submit IND for Phase 1 Trial of Intranasal Foralumab in Alzheimer's Disease Patients
12 October 2022
- Company continues to advance foralumab in CNS-related inflammatory diseases
NEW YORK, Oct. 12, 2022 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that...
Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer
29 September 2022
New York, September 29, 2022 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Matthew Davis, its Chief...
Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the “Preserving the Brain” Scientific Conference and Exhibit at the Fondazione Prada in Milan
28 September 2022
- “Effect of nasal anti-CD3 (foralumab) in animal model of Progressive Multiple Sclerosis (MS)” poster exhibit
- “Effect of nasal anti-CD3 (foralumab) in healthy subjects” poster exhibit
- “Effect of nasal anti-CD3 (foralumab) in patient with Progressive MS” poster exhibit
- Howard L. Weiner, M.D. of Brigham...
Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer
23 September 2022
New York, September 23, 2022 – Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Matthew Davis, its Chief Medical...